We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson (J&J) has disclosed that three of its subsidiaries have received three separate subpoenas from the Boston, San Francisco and Philadelphia U.S. attorney’s offices relating to marketing practices for Risperdal, Topamax and Natrecor.
A federal antitrust lawsuit filed by drug distributors against Purdue Pharma claims the drug company monopolized the OxyContin market by blocking generic versions of the drug with illegally obtained patents.
Some courts are placing drug companies in an impossible situation by failing to recognize the FDA’s preemption authority in product labeling cases, the Washington Legal Foundation (WLF) said.
A jury in a New Orleans federal court rejected product liability claims against Merck that blamed the company’s painkiller Vioxx for the heart attack of a Utah resident.
The U.S. Court of Appeals for the District of Columbia heard arguments in a landmark case to decide if terminally ill patients have a constitutional right to use drugs that have not been fully approved by the FDA.
A five-year old patent infringement case filed by Apotex backfired when a federal court dismissed the case and ordered the company to pay $3.1 million in attorneys fees after finding its patent invalid.
One of two plaintiffs in a Vioxx product liability case can no longer seek compensatory or punitive damages against Merck following a two-pronged jury verdict.
Teva Pharmaceutical will have partial marketing exclusivity once it launches rabeprazole sodium, a generic version of Eisai’s acid-pump inhibitor drug, Aciphex.
Astellas Pharma is moving to extend patent protection for its enlarged-prostate treatment Flomax, a blockbuster drug that generated more than $1 billion in sales last year, the company said.
Former FDA Commissioner Lester Crawford will have to pay $90,000 in penalties and serve three years of probation for federal fraud charges levied against him for failing to disclose financial conflicts of interest and making false statements, his attorney said.